Swiss Transfusion SRC closes 2020 with a break-even result.
The Covid-19 pandemic resulted in substantial additional expenses, both in the area of the blood supply and in that of blood stem cell donation. The Swiss Red Cross bore the majority of the additional direct expenditures in this context.
The dues that the regional blood services pay to Swiss Transfusion SRC were lowered in 2019. Since then, Swiss Transfusion SRC’s annual income in this category has been around CHF 550’000 below what it had been previously.
Transplant material from Switzerland continued to be in high demand in 2020, with the number of collection procedures reaching a new high of 70. There were slightly fewer search requests compared to 2019, also fewer confirmatory typing procedures; transplant procedures, however, were slightly up over 2019. Overall, income from donor searches and transplantation increased from CHF 14.2 million (2019) to around CHF 14.5 million.
Swiss Transfusion SRC’s mandate from the Swiss government to provide services in the area of blood stem cells does not include any funding for the registration of new donors. Swiss Transfusion SRC has to cover these expenses itself. Total registration costs per donor are CHF 140. In 2020, Swiss Transfusion SRC launched a new supporter programme designed to encourage longer-term, regular support for blood stem cell donation and thus help pay for the growth of the registry.
The 2020 financial statement shows a small profit in the area of blood stem cells and a small loss in the blood supply area.
The annual financial statement was audited by the auditors Ernst & Young according to the Swiss GAAP FER standards and the principles of the limited audit. The complete, audited annual financial statement as well as the auditor’s report can be ordered from Swiss Transfusion SRC.